 |
Research & Professional Staff
Director's Overview
The Translational Research Institute combines the drug discovery efforts at Scripps Florida with technology platforms: genomics, proteomics, and cell-based screening.
The goal of the drug discovery operation is to discover and develop small-molecule therapeutic agents for unmet medical needs in inflammation, neurodegeneration, stroke, cancer, and metabolic disorders. The operation is headed by Pat Griffin, professor and chair, Molecular Therapeutics. Groups within the TRI include Lead Identification, headed by Peter Hodder, director and associate professor of Molecular Therapeutics; Medicinal Chemistry, headed by William Roush, executive director and professor, Chemistry; Discovery Biology, headed by Phil LoGrasso, director and associate professor, Molecular Therapeutics; and Drug Metabolism and Pharmacokinetics, headed by Mike Cameron, associate scientific director.
The Cell-Based Screening Core is headed by Julie Conkright. The CBS core provides support and assay development for large scale cDNA and siRNA screens.
The Genomics Core is headed by Mat Pletcher, assistant professor, Molecular Therapeutics. The goal of this core is to provide Scripps investigators and external collaborators cutting-edge technologies in genetics.
The Proteomics Core is headed by Jennifer Busby, associate director and assistant professor, Molecular Therapeutics. Researchers in the Proteomics Laboratory focus on the application of liquid chromatography and mass spectrometry to the identification, quantitation, and characterization of proteins and posttranslational protein modifications. The laboratory is involved in scientific collaborations within Scripps Florida and with several external investigators.
TRI Informatics is headed by Chris Mader. The goal of the TRI-informatics group is to provide computational tools and services such as the development of scientific software, computational biology, drug discovery informatics and chemoinformatics.
|
|
